Clinical significance of programmed death ligand-1 and intra-tumoral CD8+ T lymphocytes in ovarian carcinosarcoma

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Zhu, Jun ^a   Wen, Hao ^a   Ju, Xingzhu ^a   Bi, Rui ^a   Zuo, Wenjia ^a   Wu, Xiaohua ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASCITES FLUID; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; OUTCOME ASSESSMENT; OVARIAN CARCINOSARCOMA; OVARY CARCINOMA; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; SURVIVAL RATE; ANTIBODY SPECIFICITY; CARCINOSARCOMA; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MESENCHYMAL STROMA CELL; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIGENS, CD274; ASCITIC FLUID; BIOMARKERS, TUMOR; CARCINOSARCOMA; CD8-POSITIVE T-LYMPHOCYTES; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85010953122     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170879     Document Type: Article

References (40)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: a cancer journal for clinicians. 2011; 61(4):212-36.
2. Rauh-Hain JA, Growdon WB, Rodriguez N, Goodman AK, Boruta DM 2nd, Schorge JO, et al. Carcinosarcoma of the ovary: a case-control study. Gynecologic oncology. 2011; 121(3):477-81. doi: 10.1016/j.ygyno.2011.02.023 PMID: 21420726
3. Sit AS, Price FV, Kelley JL, Comerci JT, Kunschner AJ, Kanbour-Shakir A, et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecologic oncology. 2000; 79(2):196-200. doi: 10.1006/gyno.2000.5956 PMID: 11063643
4. Inthasorn P, Beale P, Dalrymple C, Carter J. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. The Australian & New Zealand journal of obstetrics & gynaecology. 2003; 43(1):61-4.
5. Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecologic oncology. 2007; 105(3):657-61. doi: 10.1016/j.ygyno.2007.01.037 PMID: 17395252
6. Loizzi V, Cormio G, Camporeale A, Falagario M, De Mitri P, Scardigno D, et al. Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature. Oncology. 2011; 80(1-2):102-6. doi: 10.1159/000328794 PMID: 21677454
7. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(13):3462-73. PubMed Central PMCID: PMC4102335.
8. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. The Journal of experimental medicine. 2006; 203(4):883-95. PubMed Central PMCID: PMC2118286. doi: 10.1084/jem.20051776 PMID: 16606670
9. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature medicine. 2003; 9(5):562-7. doi: 10.1038/nm863 PMID: 12704383
10. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. International immunology. 2007; 19(7):813-24. doi: 10.1093/intimm/dxm057 PMID: 17606980
11. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. International immunology. 2015; 27(1):39-46. doi: 10.1093/intimm/dxu095 PMID: 25323844
12. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(9):3360-5. PubMed Central PMCID: PMC1805580. doi: 10.1073/pnas.0611533104 PMID: 17360651
13. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(7):2151-7.
14. Bocker W. [WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics]. Verhandlungen der Deutschen Gesellschaft fur Pathologie. 2002; 86:116-9. PMID: 12647359
15. Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny J Jr., Taylor C, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry. 2015; 23(8):541-9. PubMed Central PMCID: PMC4561627.
16. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer immunology research. 2013; 1(1):54-63. PubMed Central PMCID: PMC3885978. doi: 10.1158/2326-6066.CIR-13-0034 PMID: 24416729
17. Rauh-Hain JA, Gonzalez R, Bregar AJ, Clemmer J, Hernandez-Blanquisett A, Clark RM, et al. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. Gynecol Oncol. 2016.
18. Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016; 7(2):1486-99. doi: 10.18632/oncotarget.6429 PMID: 26625204
19. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science translational medicine. 2012; 4(127):127ra37. PubMed Central PMCID: PMC3568523. doi: 10.1126/scitranslmed.3003689 PMID: 22461641
20. Faraj SF, Munari E, Guner G, Taube J, Anders R, Hicks J, et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology. 2015; 85(3):703 e1-6. PubMed Central PMCID: PMC4695997.
21. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2012; 98(6):751-5. doi: 10.1700/1217.13499 PMID: 23389362
22. Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PloS one. 2013; 8(10):e76012. PubMed Central PMCID: PMC3790819. doi: 10.1371/journal.pone.0076012 PMID: 24124529
23. Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Droeser RA, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast cancer research and treatment. 2014; 146(1):15-24. PubMed Central PMCID: PMC4180714. doi: 10.1007/s10549-014-2988-5 PMID: 24842267
24. Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, et al. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015; 21(13):3052-60. PubMed Central PMCID: PMC4490112.
25. Schmidt LH, Kummel A, Gorlich D, Mohr M, Brockling S, Mikesch JH, et al. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PloS one. 2015; 10(8):e0136023. PubMed Central PMCID: PMC4552388. doi: 10.1371/journal.pone.0136023 PMID: 26313362
26. Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer immunology research. 2014; 2(7):690-8. PubMed Central PMCID: PMC4082476. doi: 10.1158/2326-6066.CIR-13-0224 PMID: 24866169
27. George E, Manivel JC, Dehner LP, Wick MR. Malignant mixed mullerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Human pathology. 1991; 22(3):215-23. PMID: 1706302
28. Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(6):1363-74.
29. Amant F, Vloeberghs V, Woestenborghs H, Moerman P, Vergote I. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol. 2003; 90(2):372-7. PMID: 12893202
30. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine. 2002; 8(8):793-800. doi: 10.1038/nm730 PMID: 12091876
31. Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, et al. PDL1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 2015.
32. Muhlbauer M, Fleck M, Schutz C, Weiss T, Froh M, Blank C, et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol. 2006; 45(4):520-8. doi: 10.1016/j.jhep.2006.05.007 PMID: 16876901
33. Bernhard H, Schmidt B, Busch DH, Peschel C. Isolation and expansion of tumor-reactive cytotoxic T-cell clones for adoptive immunotherapy. Methods Mol Med. 2005; 109:175-84. PMID: 15585921
34. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(51):18538-43. PubMed Central PMCID: PMCPMC1311741. doi: 10.1073/pnas.0509182102 PMID: 16344461
35. Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol. 2010; 22(2):215-22. doi: 10.1016/j.coi.2010.02.006 PMID: 20207124
36. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012; 124(2):192-8. PubMed Central PMCID: PMCPMC3298445. doi: 10.1016/j.ygyno.2011.09.039 PMID: 22040834
37. Farghaly SA. Advances in diagnosis and management of ovarian cancer. New York: Springer; 2014. xv, 270 pages p.
38. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PubMed Central PMCID: PMCPMC3563263. doi: 10.1056/NEJMoa1200694 PMID: 22658128
39. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; 33(34):4015-22.
40. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013; 73(23):6900-12. PubMed Central PMCID: PMCPMC3851914. doi: 10.1158/0008-5472.CAN-13-1550 PMID: 23975756